317 related articles for article (PubMed ID: 25849542)
1. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
[TBL] [Abstract][Full Text] [Related]
4. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC; Conner C; Hammer M
Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
10. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
Scott DA; Boye KS; Timlin L; Clark JF; Best JH
Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
14. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
15. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
[TBL] [Abstract][Full Text] [Related]
17. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
Deng J; Gu S; Shao H; Dong H; Zou D; Shi L
J Med Econ; 2015; 18(11):974-89. PubMed ID: 26134916
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]